On Wednesday, Shares of Comcast Corporation (NASDAQ:CMCSA), gained 3.51% to $62.25, hitting its highest level.
The top 20 TV episodes on Xfinity On Demand that aired live or on Xfinity On Demand during the week of June 15– June 21 were:
- True Detective (season premiere), HBO
- Ballers (season premiere), HBO
- Power (episode 3), STARZ
- Complications (series premiere, episodes 1-2), USA
- Love & Hip Hop Atlanta (episode 8), VH1
- The Bachelorette (episode 6), ABC
- America’s Got Talent (episode 4), NBC
- The Last Ship (season premiere, episodes 1-2), TNT
- Married at First Sight (finale special part 1), FYI
- Dance Moms (episode 23), Lifetime
- The Astronaut Wives Club (series premiere), ABC
- Proof (series premiere), TNT
- Chrisley Knows Best (episodes 5-6), USA
- The Brink (series premiere), HBO
- Tyrant (season premiere), FX
- The Real Housewives of Orange County (episode 2), Bravo
- Rizzoli & Isles (season premiere), TNT
- The Whispers (episode 3), ABC
- The Real Housewives of New York City (episode 11), Bravo
- Finding Carter (episode 12), MTV.
Comcast Cable is the nation’s largest video, high-speed Internet and phone provider to residential customers under the XFINITY brand and also provides these services to businesses.
Comcast Corporation operates as a media and technology company worldwide. It operates through Cable Communications, Cable Networks, Broadcast Television, Filmed Entertainment, and Theme Parks segments. The Cable Communications segment offers video, high-speed Internet, and voice services to residential and business customers under the XFINITY brand name.
Shares of Weatherford International plc (NYSE:WFT), declined -3.67% to $11.82, during its last trading session.
Weatherford International, declared that it has been named a constituent in the 2015 MSCI Global Sustainability Index Series.
The MSCI Global Sustainability Indexes are free float-adjusted market capitalization weighted indexes designed to provide exposure to companies that have high Environmental, Social and Governance (ESG) performance. The MSCI Global Sustainability Indexes aim to target sector weights that reflect the relative sector weights of the underlying indexes to limit the systematic risk introduced by the ESG selection process. Overall the MSCI Global Sustainability Indexes target coverage of 50% of the underlying MSCI parent index.
As of June 26, 2015, Weatherford was also added into the broad-market Russell 3000®Index. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
Weatherford International public limited company provides equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells worldwide.
Finally, Juno Therapeutics Inc. (NASDAQ:JUNO), ended its last trade with 2.10% gain, and closed at $54.45.
Juno Therapeutics, declared the U.S. Food and Drug Administration (FDA) accepted the Company’s investigational new drug (IND) application for JCAR017 for patients with relapsed/refractory (r/r) B cell non-Hodgkin lymphoma, or NHL. JCAR017 is a chimeric antigen receptor (CAR) T cell product candidate targeting CD19, a protein expressed on the surface of most B cell leukemias and lymphomas.
The IND enables Juno to initiate a multi-center Phase I trial exploring JCAR017 for r/r NHL, planned to start in 2015, with the potential to advance to a registration trial in 2016.
“Based on the encouraging results of JCAR017 in pediatric acute lymphoblastic leukemia, we are excited to start investigating this product candidate in non-Hodgkin lymphoma,” said Mark Frohlich, M.D., Juno EVP of development and portfolio strategy. “FDA acceptance of the JCAR017 IND for this multi-institutional study is an important milestone for Juno. Together with our planned fully-human CD19 CAR-T cell trial, combination study with AstraZeneca’s anti-PDL-1 antibody, and ongoing translational clinical trial with JCAR014, it will provide important biologic insights that will inform our future strategies.”
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
